📰 Processing Deficient Progeroid News
Processing Deficient Progeroid News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Processing Deficient Progeroid. Real-time updates on events, politics, business and more.
January 20, 2024
/PRNewswire/ -- The Progeria Research Foundation (PRF) today announced a new milestone with the approval of Zokinvy™ (lonafarnib) by the Japanese Ministry of...
August 14, 2023
Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in... -Today at 04:06 pm- MarketScreener
June 29, 2023
Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align with focus on avexitide; ext...
March 16, 2023
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
November 3, 2022
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
May 5, 2022
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
January 6, 2022
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
November 4, 2021
/PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies...
March 9, 2021
Global Phase 3 D-LIVR study enrollment completion planned in 2021 Peginterferon Lambda for HDV Global Phase 3 LIMT-2 study initiation planned in 2021 Zokinvy™ (lonafarnib) for Progeria and Processing-Deficient Progeroid Laminopathies U.S. commercial launch in January 2021 EMA decision expected in 2H21 Lambda for COVID-19 Lancet Respiratory Medicine (Feld et al, 2021) Considering strategic options to advance program Avexitide for Post-Bariatric Hypoglycemia (PBH) Positive Phase 2 PREVENT stu...
March 9, 2021
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) to Complete Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Strong Cash Position with $176 Million Pro-Forma Cash to Begin 2021 News provided by Share this article Share this article PALO ALTO, Calif., March 9, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical stage compan...